Regeneron edges closer to Eylea market exclusivity amid biosimilar threats
New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Fed Circ oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
13 February 2025 The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.
4 February 2025 Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis and Formycon failed to convince that the patent-in-suit was invalid.